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Calcium carbonate nanoparticles 
stimulate cancer cell 
reprogramming to suppress 
tumor growth and invasion 
in an organ‑on‑a‑chip system
Sandra F. Lam1, Kevin W. Bishop1, Rachel Mintz1, Lei Fang1,2 & Samuel Achilefu1,2,3,4*
The acidic microenvironment of solid tumors induces the propagation of highly invasive and 
metastatic phenotypes. However, simulating these conditions in animal models present challenges 
that confound the effects of pH modulators on tumor progression. To recapitulate the tumor 
microenvironment and isolate the effect of pH on tumor viability, we developed a bifurcated 
microfluidic device that supports two different cell environments for direct comparison. RFP‑
expressing breast cancer cells (MDA‑MB‑231) were cultured in treatment and control chambers 
surrounded by fibrin, which received acid‑neutralizing  CaCO3 nanoparticles  (nanoCaCO3) and cell 
culture media, respectively. Data analysis revealed that  nanoCaCO3 buffered the pH within the 
normal physiological range and inhibited tumor cell proliferation compared to the untreated control 
(p < 0.05). Co‑incubation of cancer cells and fibroblasts, followed by  nanoCaCO3 treatment showed 
that the nanoparticles selectively inhibited the growth of the MDA‑MB‑231 cells and reduced cellular 
migration of these cells with no impact on the fibroblasts. Sustainable decrease in the intracellular pH 
of cancer cells treated with  nanoCaCO3 indicates that the extracellular pH induced cellular metabolic 
reprogramming. These results suggest that the  nanoCaCO3 can restrict the aggressiveness of tumor 
cells without affecting the growth and behavior of the surrounding stromal cells.
During tumor progression, cells undergo many changes to cope with the harsh environment that is created by 
the rapidly expanding cells. One change that occurs is the acidification of the tumor  microenvironment1–5. This 
physiologic condition is driven by the upregulation of glycolysis and proton transporters that allow the cancer 
cells to thrive in acidic  conditions6–8. Acidic tumor microenvironment (TME) increases the invasion, metastasis, 
proliferation, and drug resistance of cancer  cells1,9–14. One approach to combat these effects is to use therapies 
that buffer the TME to maintain normal physiology at a pH of approximately 7.4.
Previous studies have shown that sodium bicarbonate successfully decreased tumor  metastasis15,16. However, 
oral administration of the product ad libitum does not target the tumor directly but instead raises the global 
extracellular pH, which could induce metabolic alkalosis and potential morbidity. A variety of other approaches 
have been explored to modulate the acidic TME or use this phenomenon to deliver drugs via pH-responsive 
 NPs17,18 and cell-penetrating  peptides19. Among the various methods that modulate the acidic TME and enhance 
drug  delivery20–24,  acid-neutralizing  CaCO3 nanoparticles  (nanoCaCO3) have been particularly effective due to 
their high payload and buffering capacity, facilitating drug  delivery17,25 and direct pH modulation of the  TME26. 
 NanoCaCO3 have few side effects, as they degrade into calcium and  CO2 and only increase the extracellular pH 
to a maximum of 7.426. However, deciphering the effects of  nanoCaCO3 on tumor cells in the complex in vivo 
environment is challenging. Without a method to dynamically quantify the number of nanoparticles that accu-
mulate in the tumor, the net effect of pH on inhibiting the acidic extracellular pH in tumors remains unclear. 
This situation can cause significant variability in the results obtained and requires extensive ex vivo analysis to 
identify how  nanoCaCO3 treatment affected tumor migration.
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In this study, we determined the effect of pH changes on tumor survival and migration by simulating in vivo 
flow parameters in a controlled environment using microfluidic devices. Microfluidic devices have the ability 
to grow multiple cells in a 3D environment and offer precise control of fluid  flow27–30. Using a transparent poly-
mer, polydimethylsiloxane (PDMS), for device fabrication permits real-time fluorescence microscopy of the 
cell growth. A bifurcate design allows half of the tissue chambers to receive  nanoCaCO3, while the other half 
receives cell culture medium. The design enabled us to directly compare the growth of tumor cells treated with 
small-sized  nanoCaCO3 (< 120 nm) to those without treatment on the same device. We demonstrate that not 
only did  nanoCaCO3 increase the extracellular pH asymptotically to 7.4, but they also inhibited tumor growth 
and migration.
Materials and methods
Cell culture. RFP expressing MDA-MB-231 human metastatic breast cancer cells were purchased from Cell 
Biolabs (San Diego, CA), and skin fibroblast cells were purchased from the Coriell Institute (Camden, New 
Jersey). MDA-MB-231 cells served as an appropriate model for our study because of their sensitivity to acidic 
 TME31. All cells were grown in Dulbecco’s Modified Eagle Medium (DMEM, ThermoFisher, Waltham, MA) 
containing 10% fetal bovine serum (FBS, Sigma-Aldrich, St. Louis, MO), 1% L-glutamine (ThermoFisher), and 
1% penicillin streptomycin (ThermoFisher). They were cultured in a humidified incubator at 37 °C and 5%  CO2.
Microfluidic device design and simulations. We developed a microfluidic device that can incorporate 
the experimental and control conditions on the same chip. Two tissue chambers (0.061  mm3) were located near 
the upper portion of the device (experimental), and two were located near the lower portion of the device (con-
trol). Smaller chambers of plain fibrin (0.015  mm3) were placed adjacent to the tissue chambers to measure cellu-
lar migration. Lastly, media channels were placed on the outside of fibrin chambers. By manipulating the hydro-
static pressure difference between media channels, we were able to control fluid velocities to mimic physiological 
values. To ensure proper separation between the experimental and control tissue chambers, a larger “waste” 
channel was placed between the two compartments to inhibit contamination between chambers (Fig. 1A). Addi-
tionally, flow through this channel was constantly maintained via connection to a microfluidic syringe pump.
We then used AutoCAD to construct a computer-aided design of the device. Standard photolithography 
methods were used to create a silicon mold of the microfluidic  devices32. Briefly, SU-8 2050 (MicroChem, 
Newton, MA) was spun on to a silicon wafer to a height of 100 μm. Using the printed pattern, the design was 
crosslinked into the photoresist with ultraviolet exposure. After developing the pattern out of the mold, it was 
silanized before pouring polydimethylsiloxane (PDMS, Dow Corning, Elizabethtown, KY) on top of it. The 
PDMS mixture was prepared from a 10:1 (w/w) polymer to curing agent solution, which was mixed thoroughly. 
After degassing the PDMS, it was cured overnight in a 65 °C oven. The PDMS was then peeled off, and the inlet 
and outlets of the device were punched with a 16-gauge needle. To bond the PDMS device to a glass slide, both 
pieces were cleaned and placed under plasma treatment for 1 min at 250 mTorr. After sealing the pieces of the 
device to the glass slide, the material was placed in a 120 °C oven for at least 15 min. The device was sterilized 
under ultraviolet light for at least 8 h before use.
We used COMSOL Multiphysics 5.4 (Burlington, MA) to simulate interstitial flow within the microfluidic 
devices. A 2D steady-state solution of incompressible Navier–Stokes equations was solved to calculate flow 
throughout the device using the Porous Media Flow module. A no slip boundary condition was used for all the 
walls, and the properties of the device have been previously  published27,33.
NanoCaCO3 fabrication and size characterization. NanoCaCO3 were synthesized using a gas diffu-
sion  method34. Briefly, a solution of  CaCl2 hexahydrate (1 g; 4.6 mmol; Sigma–Aldrich) in 200 mL of anhydrous 
ethanol was added to a 400 mL beaker, which was covered with Parafilm in a desiccator containing Drierite. To 
allow gas exchange, the Parafilm cover was punctured with small holes. The beaker was surrounded by 16 glass 
vials (20 mL) filled with dry ammonium bicarbonate (typically 20 g per vial). Seeding and nanoparticle forma-
tion was allowed to occur over 5 days in a vacuum. The solid nanoparticles were obtained by centrifuging the 
suspension in ethanol at 6800 g for 10 min in 1 mL Eppendorf tubes, air-dried over 24 h, and stored at 4 °C. The 
materials were reconstituted in DMEM before use.
Transmission electron microscopy (TEM) images of the  nanoCaCO3 were captured using a FEI Tecnai Spirit 
Transmission Electron Microscope (FEI, Hillsboro, OR, USA) operating at an acceleration voltage of 200 kV, as 
described  previously34. TEM grids coated with a layer of Formvar were used throughout these studies. Dynamic 
light scattering measurements of the nanoparticles in ethanol, distilled water, phosphate buffered saline (PBS), 
or serum were acquired with a Malvern Zetasizer Nano ZS (Malvern Instruments Ltd., Malvern, UK) instrument 
equipped with a 633 nm laser. Three measurements were conducted for each sample with at least 10 runs, each 
run lasting 10 s. All sizes reported were based on the intensity average.
Microfluidic experimental design and setup. For each experiment, fibrin was used to create the extra-
cellular matrix for the TME. Fibrinogen (Sigma-Aldrich, St. Louis, MO) and thrombin (Sigma-Aldrich) were 
prepared in PBS (Gibco) for a final concentration of 16 mg  mL−1 and 50 U  mL−1 respectively. MDA-MB-231 
cells were trypsinized and resuspended in the fibrinogen solution at a concentration of 3 ×  106 cells  mL−1. The 
thrombin was then added to this mixture to initiate the polymerization process. Before the solution completely 
polymerized, it was pipetted into the tissue chambers of the device. Immediately after loading the cells into the 
device, plain fibrin was loaded to the adjacent chambers using the same method. The device was then placed 
in a 37 °C incubator for 30 min before media was added to the media channels Tygon tubing (Saint-Gobain, 
Valley Forge, PA) was connected to the inlets and outlets of the waste stream channel and attached to a syringe 
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Figure 1.  Device design and setup. (A) Design of the microfluidic device. Cells in fibrin are loaded into the 
brown chambers. Plain fibrin is loaded in the adjacent chambers to quantify cellular migration. Media is flown 
through the pink channels to feed the tissue. The flow patterns of the device are illustrated by the arrows. The 
two upper chambers will receive media with  CaCO3 nanoparticles (blue arrows), while the two lower chambers 
will receive plain media (red arrows). The central chamber is connected to a microfluidic pump to serve as a 
“waste” stream so the upper and lower chambers can maintain independence from each other. (B) Experimental 
setup of the microfluidic device. Pipette tips are used to feed the tissue chambers on the outside of the device, 
while the middle media channel is connected to a microfluidic pump via tubing. (C) Fluid velocity (µm  s−1) 
distributions are shown in the surface map (left). The streamlines of interstitial flow are illustrated with pink 
lines. Quantification of velocities along the black arrow are shown in the graph to the right. The boxed regions 
in the graph represent the fluid velocities within the tissue chambers. (D) FITC-dextran flow through the top 
media channel to show that the fluorescent signal is attenuated towards the lower chambers. This confirms that 
there is no crosstalk between the upper and lower chambers. Scale bar = 200 µm. (E) Visual confirmation of the 
presence of  CaCO3 nanoparticles. The black punctate marks in the tissue chamber and media lines serve as a 
visual representation that the  CaCO3 nanoparticles are reaching the tissue chamber through the media lines.
4
Vol:.(1234567890)
Scientific Reports |         (2021) 11:9246  | https://doi.org/10.1038/s41598-021-88687-6
www.nature.com/scientificreports/
pump (Fig. 1B). A syringe containing media was flowed constantly for a rate of 10 nL  s−1 throughout the experi-
ments. After the device was placed in the incubator overnight, the media in the top channel was replaced with 
the DMEM media containing  nanoCaCO3 at selected concentrations of ≤ 0.8 mg  mL−1. The media was changed 
every 2 days for the 6-day experiment. For the experiment containing cancer and fibroblast cells, the cells were 
loaded at a concentration of 1.71 ×  106 cells  mL−1 and 4.29 ×  106 cells  mL−1, respectively.
Imaging and tumor progression analysis. Both fluorescent and brightfield images were acquired at 
the start and end of each experiment using an EVOS FL Cell Imaging System (ThermoFisher). In the experi-
ments containing fibroblasts, a live stain was used at the end of the experiment. Briefly, Calcein AM was used to 
determine cell viability and label the live cells with green fluorescence. First, the cells were washed with Hanks’ 
Balanced Salt Solution (HBSS, Gibco) for an hour before incubating the cells in the dye for at least 2 h. All images 
were cropped to contain either the top, center, or bottom chambers. MDA-MB-231 tumor area was measured 
with ImageJ by calculating the red fluorescent area. The fibroblast cells remained nonfluorescent to ensure their 
properties were not altered, and their area was traced manually during image analysis to calculate the fibroblast 
area on the initial day of loading. At the end of the experiment, fibroblast area was determined by subtracting 
the red fluorescent area (MDA-MB-231 cell area) from the green fluorescent area (total viable cellular area). The 
parameters for growth and migration were calculated using the following equations:
pH measurements. To estimate how  nanoCaCO3 were affecting the tumor microenvironment, pH meas-
urements were made using 24 well plates. First, MDA-MB-231 cells were seeded in the wells at a concentration of 
3.0 ×  106 cells  mL−1. The next day, the media was replaced with either plain media (control) or media containing 
0.8 mg  mL-1  nanoCaCO3 (experimental). After 3 more days, the media was collected, and a pH probe (AB15 
Basic, ThermoFisher) was used to measure the pH of the media in the wells.
Additionally, the intracellular pH was determined using a pHrodo Green AM Intracellular pH Indicator 
(ThermoFisher) following the manufacture’s protocol. With this dye, higher fluorescent intensities indicate a 
lower pH. Therefore, to correlate fluorescent intensities with pH values, a pH Calibration Buffer Kit (Ther-
moFisher) was used.
Statistical analysis. To test the effectiveness of  nanoCaCO3 on tumor growth inhibition, a Mann–Whitney 
test was used to compare the control with the experimental data sets. GraphPad Prism was used for these cal-
culations, and the criterion for statistical significance was p < 0.05. All results are presented as mean ± standard 
deviation.
Results
Microfluidic device characterization. We developed a bifurcated microfluidic device that allowed two 
cell environments to be compared side by side (Fig. 1). The device was designed to control interstitial flow rates 
depending on the drop in pressures along the tissue chambers. A low-pressure waste stream flowed between the 
control and treatment sides. Media diffused through each chamber from high pressure to low pressure and was 
cleared by the central waste stream. We incorporated 6 pores that connect the tissue chambers to fibrin cham-
bers and media channels, which were specifically designed to be capillary burst valves to maintain the cells in 
each compartment during the cellular loading process. Fluid flow direction was determined by the difference in 
hydrostatic pressure head between the top and bottom channels. The flow was designed to incorporate velocities 
between 1–10 µm  s−1 to replicate physiological interstitial fluid flow (Fig. 1C). Fluid velocities were quantified 
along the black arrow and plotted as velocity vs. distance (Fig. 1C). The velocities in the tissue chamber are 
represented by the black boxes. The tissue chambers have interstitial flow rates in the physiological range of 
1–10 µm/s. This event was also observed in the waste channel stream, which was pumped at a fast flow (up to 
55 µm  s−1) rate to prevent cross-communication between the experimental and control conditions. To further 
confirm this process, fluorescein isothiocyanate-dextran (FITC-dextran) was flown through the top media chan-
nel for a day and then imaged. No fluorescent signal in the bottom chambers was observed (Fig. 1D), indicating 
that the experimental and control conditions can co-exist on the same device without cross-contamination.
NanoCaCO3 synthesis and characterization. NanoCaCO3 were prepared by the method reported 
 previously34. The transition of the solution from clear to white and cloudy indicates the nucleation and forma-
tion of the nanoparticles. Depending on the particle size desired, this reaction can be stopped at different time 
points. We obtained optimal yield and stable product by reacting 1 g  CaCl2 in 200 mL ethanol with ammonium 
carbonate, a carbonate source over 5 days. The size and morphology of the synthesized  nanoCaCO3 were deter-
mined by TEM and dynamic light scattering (DLS) (Fig. 2). A representative TEM micrograph revealed that 
the  nanoCaCO3 were primarily spherical, with an average size of 78.6 ± 7.6 nm (Fig. 2A). The  hydrodynamic 
diameter (Dh) size of 120.0 nm ± 29.3 nm from DLS (Fig. 2B) was larger than the TEM mean size, probably due 
to a combination of solvation effect and  aggregation35. Therefore, we investigated the stability of  nanoCaCO3 in 
Growth ratio =
Cellular area on final day
Cellular area on initial day
Migration =
Total cellular area in the top or boottom chamber
Total cellular area in the central chamber
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distilled water, PBS, and serum. Unlike the TEM images for the  nanoCaCO3 in ethanol, we found that suspen-
sions of the nanoparticles in water or PBS formed large aggregates (Fig. 2C,D), suggesting that the less than 30% 
DLS size increase in ethanol is consistent with previous  reports35. In contrast, resuspension of the nanoparticles 
in serum retained a high level of monodispersity (Fig. 2E). For this reason, we dispersed the nanoCaCO3 in 
media (DMEM) containing 10% FBS throughout this study (Fig. 2F).
Dose–response of MDA‑MB‑231 cells to  nanoCaCO3. MDA-MB-231 cells were loaded in the central 
tissue chamber and plain fibrin in the adjacent chambers (Fig. 1A). The control (bottom) and treatment (top) 
chambers received only media and  nanoCaCO3, respectively. Although both chambers were placed on the same 
device, the flow of media through the waste stream ensures that the two conditions do not come in contact with 
each other. Treatment chambers received 0.2, 0.4, 0.6, and 0.8 mg  mL−1 solution of  nanoCaCO3, and imaging 
was performed over the time course of the experiment. Brightfield images of black punctate specs inside the tis-
sue chamber provided visual evidence that the  nanoCaCO3 entered the tissue chamber (Fig. 1E). Migration of 
 nanoCaCO3 embedded inside the fibrin at a concentration of 1.6 mg  mL−1 provided additional visual evidence 
that the particles reached the cancer cells (Fig. 3A).
A comparison of the cell proliferation rate between control and chamber treated with 0.2 mg  mL−1 at day 5 
did not show any statistical difference, with the control group exhibiting an average of 10.09 ± 3.37 growth ratio 
(Fig. 3). In contrast, cells treated with  nanoCaCO3 concentrations > 0.2 mg  mL−1 displayed a concentration-
dependent inhibition of tumor growth (Fig. 3D). The lowest tumor growth ratio of 5.40 ± 1.20 was observed 
for the 0.8 mg  mL−1 treatment group, which was significantly lower than the control group (p < 0.05) at day 5. 
Furthermore, the quantification of the growth ratios shows that the MDA-MB-231 cells grown in the fibrin 
embedded with  nanoCaCO3 had significantly lower growth than the control cells (Fig. 3B). With the goal of 
maximizing tumor inhibition, we used 0.8 mg  mL−1 of  nanoCaCO3 in all subsequent experiments.
pH quantifications. Acidic TME occurs as cancer cells proliferate. To simulate this in vivo process, we cul-
tured MDA-MB-231 cells in 24 well plates and allowed the cells to grow for 3 days with or without  nanoCaCO3. 
Subsequent measurement of the media pH showed that the control group was significantly more acidic (average 
pH of 7.14 ± 0.04) than cells treated with  nanoCaCO3 (average pH of 7.25 ± 0.07), reflecting the buffering effects 
of the nanoparticles (Fig. 4A). Changing the extracellular pH of cancer cells is expected to induce a response 
 intracellularly36. Using an intracellular pH sensor (pHrodo Green AM) that increases its fluorescence intensity 
with pH  increase37, we found that MDA-MB-231 cells exposed to  nanoCaCO3 had significantly higher fluo-
rescence intensity compared to the control group (Fig. 4B). We used a Calibration Buffer Kit to create a linear 
relationship between fluorescence intensity and intracellular pH (Fig. 4C). Correlating the intensity to a specific 
pH using this plot, we were able to determine the intracellular pH of 7.6 ± 0.09 and 7.05 ± 0.23 for the untreated 
and treated cells, respectively (Fig. 4D).
Figure 2.  CaCO3 nanoparticle characterization. (A) Transmission electron microscope image of  nanoCaCO3 
dispersed in ethanol before drying the nanoparticles shows spherical particles with the size of 78.6 ± 7.6 nm. 
Scale bar = 200 nm (main panel); 100 nm (inset). (B)  NanoCaCO3 were dispersed in ethanol for dynamic light 
scattering measurement, showing an average intensity-based size of 120.0 nm ± 29.3 nm. Average number of 
particles-based size measurement is 101.8 ± 24.7 nm (not shown). (C–F) TEM images of  nanoCaCO3 after 
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Figure 3.  Nano  CaCO3 effects on MDA-MB-231 cell growth. (A) Representative images of the MDA-MB-231 
cells loaded in fibrin gels. Images of the start (top) and end (bottom) of the experiment with fibrin gels 
containing 1.6 mg  mL−1 concentration of  CaCO3 nanoparticles is shown. Scale bar = 200 µm. (B) Embedding 
 CaCO3 nanoparticles inside fibrin. After embedding  CaCO3 nanoparticles inside our fibrin gel, the 
quantification of tumor growth showed significantly more growth under the control conditions. **** p < 0.0001. 
(C) Representative images of MDA-MB-231 cells expressing RFP grown in varying concentrations of  CaCO3 
nanoparticles. Images of the tissue chambers right after loading are shown in the top row, and images at the end 
of the experiment are shown in the bottom row. Scale bar = 200 µm. (D) Quantification of the effects of  CaCO3 
nanoparticles at varying concentrations. At 0.8 mg  mL−1, tumor growth was significantly inhibited compared to 
the control condition. * p < 0.05.
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NanoCaCO3 do not inhibit fibroblast growth, but do affect tumor migration. Cancer-associated 
fibroblasts (CAFs) constitute the major component of breast cancer  stroma38,39. Through the fibroblast-tumor 
cell signaling axis, cancer cells can migrate, escape treatment and develop resistance. To simulate this in vivo 
condition, we co-incubated fibroblasts with MDA-MB-231 cells in the tissue chamber and measured the growth 
ratio of each cell type (Fig. 5A). Analysis of the growth pattern showed that the control group had a growth 
ratio of 5.06 ± 2.85 for the MDA-MB-231 cells and 5.07 ± 2.12 for the fibroblast cells (Fig. 5B). In cells treated 
with 0.8 mg  mL−1  nanoCaCO3, the nanoparticles significantly inhibited the cancer growth ratio (2.10 ± 0.53) but 
not the fibroblast growth ratio (5.07 ± 1.77). These results demonstrated that  nanoCaCO3 can selectively inhibit 
tumor growth without harming surrounding non-tumor host cells such as fibroblasts. However, given the dual 
role of CAFs in the  TME40, the full impact of this selective inhibition is unknown at this time.
An essential function of cancer-associated fibroblasts is to support tumor  migration41. Co-incubation of 
fibroblasts with MDA-MB-231 cells showed that the cancer cells were more migratory than in the absence of 
fibroblasts (Fig. 5C). Additionally, the MDA-MB-231 cells with fibroblasts had statistically more migration 
against the flow of media (top migration chamber) than with the flow of media (bottom migration chamber). 
The migration parameter was 0.78 ± 0.47 against flow and 0.07 ± 0.45 with flow. However, with the addition of 
 nanoCaCO3, this migration pattern was diminished and not statistically significant, as indicated with the migra-
tion parameter values of 0.80 ± 0.22 and 0.25 ± 0.23 against and with flow respectively (Fig. 5D). The moderate 
increase of cancer cell migration with flow upon treatment with nanoCaCO3 suggests that these nanoparticles 
could mobilize cancer  cells42, making them more susceptible to chemotherapy when used as combination therapy.
Figure 4.  Nano  CaCO3 effects on pH. (A) After the cells were seeded in 24 well plates and received media with 
or without  CaCO3 nanoparticles, the media was collected and a pH probe was used to make measurements. 
The control group (red) had significantly lower pH than the experimental group (blue). (B) A pHrodo Green 
AM Intracellular pH Indicator dye was used compare the intracellular pH of the tumor cells with or without 
 CaCO3 nanoparticles. (C) Higher fluorescent intensity indicates lower intracellular pH, and a Calibration 
Buffer Kit was used to correlate fluorescent intensity with intracellular pH. (D) The average intracellular pH 
of the MDA-MB-231 cells without nanoparticles was significantly higher than those grown with nanoparticles 
indicating a more alkaline intracellular pH. Scale bar = 100 µm, * p < 0.05.
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Figure 5.  CaCO3 nanoparticle effects on varying tissue types. (A) Fluorescent and brightfield microscopy 
images of the control chambers (top row) and experimental chambers (bottom row) fed with  CaCO3 
nanoparticles. The left two columns include images taken right after loading of MDA-MB-231 expressing 
RFP and brightfield images of both cancer and fibroblast cells. The right two columns are images of the 
MDA-MB-231 cells at the end of the experiment as well as a live stain shown in GFP. Scale bar = 200 µm. (B) 
Quantification of the growth of MDA-MB-231 and fibroblast cells with and without  CaCO3 nanoparticles. The 
data shows that there was significant inhibition of tumor growth when the nanoparticles were introduced. On 
the other hand, there was no significant difference between the fibroblasts that were grown with or without 
nanoparticles. *, p < 0.05; NS, not significant. (C) Quantification of cellular migration with and against the flow 
of media. Without the presence of nanoparticles, the MDA-MB-231 cells migrate against flow, suggesting more 
aggressive behavior. In the presence of nanoparticles, there was not a significant difference between migration 
with or against flow. This suggest that  CaCO3 nanoparticles can inhibit the invasive behavior of MDA-MB-231 
cells without the nanoparticles. ****, p < 0.0001. (D) MDA-MB-231 cells in the presence of fibroblasts are more 
migratory than without fibroblasts. To compare migratory vs growth of the MDA-MB-231 cells, we calculated a 
parameter that divided the cell area in the top and bottom chambers (migration) by the cell area in the middle 
chamber (growth). Using this parameter, we can see that the MDA-MB-231 cells growth with fibroblasts (red) 
are significantly more migratory than the devices with only tumor cells (green).
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Discussion
Acidic TME is one of the hallmarks of solid  tumors1. Previously considered a side product of the Warburg 
effect, new evidence supports the view that cancer cells intentionally harness acidic conditions to activate tissue 
degrading enzymes and alter the metabolism of stromal  cells3. Tumor acidity is associated with invasive and 
metastatic behavior, which leads to higher morbidity  rates43,44. Previous studies have used this phenomenon to 
activate or release drugs selectively in the acidic  TME45. An interesting development is the potential use of acid-
neutralizing products to inhibit tumor  growth45. Studies using sodium carbonate infusion clearly demonstrated 
that the neutralizing effect can inhibit tumor  growth44. Unfortunately, clinical translatability of this approach 
is not realistic due to the potential induction of alkalosis. Recent studies have attempted to overcome this chal-
lenge by using nanoparticles to buffer the TME, thereby preventing an increase in  acidity46,47. Regardless of the 
method, the complex in vivo environment complicates the delivery and prolonged retention of the buffering 
agents in the TME.
Organ-on-a-chip technologies present a unique opportunity to culture cells in a 3D microenvironment that 
is more representative of human physiology than the traditional 2D cell culture. In addition, microfluidic devices 
can provide precise control over factors such as chemical gradients and fluid flow velocities. Thus, this platform 
can be used to simulate critical factors of human microenvironments, such as interstitial fluid flow. Other studies 
have used microfluidic devices to study MDA-MB-231  cells48. However separate conditions are often imple-
mented on separate devices. In this study, we developed microfluidic devices that have four separate cell culture 
chambers with the ability to receive both media and agents for diverse treatment conditions. By supporting 
multiple conditions on the same device, our system minimizes variability by maintaining identical temperature 
or gas  (O2 and  CO2) levels throughout the device while seamlessly changing the media simultaneously to opti-
mize test conditions. The versatility of our system allows us to incorporate extracellular matrix proteins such as 
fibrin and co-incubate stromal cells such as fibroblasts with tumor cells to simulate the in vivo TME. Employing 
microfluidic techniques, we have shown that persistent buffering of the TME with  nanoCaCO3 inhibited tumor 
growth and migration. By connecting a waste stream to a fluidic pump, both the treatment (upper chambers) 
and control (lower chambers) conditions were implemented on the same device for direct comparison.
Quantification of the TME acidity revealed that cells treated with  nanoCaCO3 in well plates maintained an 
average pH of 7.25 ± 0.07, which is significantly higher than the control cell population that had an average pH of 
7.14 ± 0.04. Although the expected pH of 7.4 was not attained, the differential buffering capacity of  nanoCaCO3 
compared to the untreated control was significant under static conditions. Given the small size of the cell popula-
tion, the actual extracellular pH may be higher if measured adjacent to the secreting membrane regions. Under 
dynamic conditions, we imagine the buffering capabilities of the  nanoCaCoO3 would bring the system to a pH 
closer to the expected 7.4 value.
Previous studies have shown that cancer cells undergo significant reprogramming in response to changes in 
the extracellular  pH49. To test if  nanoCaCO3 altered cancer cell metabolism, we measured the intracellular pH 
response to extracellular pH perturbation. The control group had a more alkaline intracellular pH (7.60 ± 0.09) 
than the treated group (7.05 ± 0.23). This result is consistent with the findings that during tumor progression, 
the intracellular pH becomes more alkaline as the extracellular pH  decreases50–53. Our results suggest that 
 nanoCaCO3 induced cell reprogramming in response to the change in the microenvironment. The significant 
increase in intracellular acidity points to a mechanism where  nanoCaCO3 alters the efflux rate of protons in the 
cells. If the observed reduction in cancer cell proliferation in the presence of  nanoCaCO3 is caused by an increase 
in the intracellular proton concentration, coupling  nanoCaCO3 therapy with drugs that are effective under acidic 
conditions will usher a new combination therapeutic strategy for cancer.
Another interesting observation from this study is the effect of fibroblasts on the behavior of MDA-MB-231 
cells. Co-incubation of the tumor cells with fibroblasts increased the migratory characteristic of the cancer cells, 
indicating the enhancement of a more invasive tumor phenotype. This tendency decreased in the presence of 
 nanoCaCO3. Furthermore, with the fibroblasts present, the tumor cells had a penchant for migrating against 
the flow of media. This observation recapitulates in vivo conditions where cancer cells adopt the spindle shape 
of fibroblasts to propel their metastatic tendencies against flow  gradients54. Together, our results suggest that 
tumor cells grown in the presence of fibroblasts exhibit more aggressive behavior than without fibroblasts. 
Lastly,  nanoCaCO3 inhibited the migratory effects of MDA-MB-231 cells in the presence of fibroblasts. While 
the molecular mechanisms of these mechanochemical events need further studies, the pronounced effects of 
nanoCaCO3 on cancer cells compared to CAFs could be attributed to the inverse role these cells play in the TME. 
For example, CAFs are known to secrete proteins in the TME that reabsorb the lactate cancer cells  produce55, 
suggesting that nanoCaCO3 will have minimal effect on the non-lactic acid producing cells. Our work adds to 
the body of evidence supporting the inclusion of drugs that can sustainably buffer the extracellular pH of solid 
tumors in combinational therapies. Extension of this promising finding to other cancer cell types will determine 
the broad applicability of the phenomenon in diverse cancer treatment.
With the ability to grow various cell types in the same device, we have shown that  nanoCaCO3 do not affect 
fibroblast growth. While the nanoparticles significantly decreased the tumor growth, there was no significant 
change in fibroblast proliferation. An interplay between cancer cell killing therapies and those that can protect 
stromal cells requires knowledge of combination therapies that will achieve maximum effect. Although additional 
studies are warranted, our result points to a paradigm where  nanoCaCO3 could sensitize  cancer cells to standard 
of care therapies without damaging stromal cells.
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Conclusions
The microfluidic device provides a platform to expand drug testing and examine the effects of cancer therapies 
on multiple organ types. Using microfluidic devices, we can precisely control the cellular microenvironment. 
This approach allowed us to recapitulate some in vivo conditions under well-controlled conditions. Our results 
reveal the multidimensional therapeutic effects that  nanoCaCO3 can exert on cancer cells. By buffering the 
extracellular pH of tumors above 7.2,  nanoCaCO3 were able to alter the trajectory of cancer cells by increasing 
the intracellular acidity, inhibiting the migratory tendencies, and preventing the proliferation of more invasive 
phenotypes of these cells without harming non-tumor cells. Each of these effects presents an opportunity to 
leverage the vulnerability of cancer cells in the presence of  nanoCaCO3 to design combination therapies and 
potentiate the therapeutic effect of drugs.
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